Dr. John Restaino, with Restaino Law, LLC. located in Denver, CO., is and has been Special Of-Counsel to the Sanders Phillips Grossman firm on several litigations including, currently, the opioid ‘mass fatality crisis’ litigation, transvaginal mesh and talc/ovarian cancer litigation. Dr. Restaino practiced surgery of the foot and ankle from 1980 to 1990, prescribing opioids during that time and has practiced at the law since 1991. He obtained his MPH from the Division of Epidemiology at the Johns Hopkins Bloomberg School of Public Health in 2008. Dr. Restaino is an Adjunct Associate Professor at the University of South Carolina College of Pharmacy where he is actively involved in scientific pharmacovigilance.
He has been or is the chair or co-chair of the Expert & Science Committees of numerous federal MDLs dating back to the Diet Pill MDL and is currently involved in both the medical and legal evaluation of the opioids, transvaginal mesh, the proton pump inhibitors Onglyza, Risperdal, and, through his work at the University of South Carolina, has been extensively evaluation the issue of fluoroquinolone-associated disability disorder including aortic aneurysms, aortic dissections, sudden death and cardiac valvulopathy. Dr. Restaino has been appointed as the chair of the epidemiology subcommittee within the Talcum Powder MDL.
He has assisted in the development the science and experts from across the world in many of the mass tort litigations since 1991. In addition, he has successfully defended experts under Daubert while successfully challenging defense experts. Dr. Restaino has been involved in multiple mass tort trials including those involving Rezulin, PPA and Vioxx.
Dr. Restaino is asked to lecture across the country at both medical and legal programs. Dr. Restaino has also been a guest lecturer at both law schools and medical schools including the University of South Carolina, Harvard and Johns Hopkins.
Dr. Restaino has published peer-reviewed medical articles in addition to legal articles and written chapters in pharmaceutical law textbooks.